BioSyent Inc. (TSXV: RX)
Health Care · Pharmaceuticals · CA
CA$15.69
-0.06% today · +30.8% 1Y
BioSyent Inc. (TSXV: RX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $128.27M and employs 60 people.
Over the last twelve months the share price has gained 30.8%, trading between 10.65 and 15.80.
Tweenvest scores BioSyent Inc. across four factors: quality 86/100, value 44/100, growth 62/100, dividend 58/100. Its strongest factor is quality.
RX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $128.27M
- Revenue (TTM)
- $39.20M
- P/E
- 18.20
- EPS
- 0.86
- Dividend yield
- 1.42%
- Beta (5Y)
- 0.63
- 52-week high
- CA$15.80
- 52-week low
- CA$10.65
- Avg volume (3M)
- —
- Shares outstanding
- 11.31M
- Employees
- 60
- Next earnings
- —
About BioSyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
- ISIN
- CA0906901081
- Founded
- 2006
- Listed since
- May 8, 1996
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.